Meeting Banner
Abstract #0201

Impact of Factors Affecting the Accuracy of Breast MRI in Determining Residual Tumor Size Following Neoadjuvant Chemotherapy

Jeon-Hor Chen1, 2, Shadfar Bahri1, Rita S. Mehta3, Philip M. Carpenter4, Christine E. Mclaren5, Wen-Pin Chen6, David J. B. Hsiang7, Min-Ying Su1

1Center for Functional Onco-Imaging,Department of Radiological Sciences, University of California Irvine, Irvine, CA, United States; 2Department of Radiology, E-Da Hospital and I-Shou University, Kaohsiung, Taiwan; 3Department of Medicine, University of California Irvine, Irvine, CA, United States; 4Department of Pathology, University of California Irvine, Irvine, CA, United States; 5Department of Epidemiology, University of California Irvine, Irvine, CA, United States; 6Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, United States; 7Department of Surgery, University of California Irvine, Irvine, CA, United States


This study was to investigate the role of multiple factors, including tumor characteristics, NAC regimens, MR systems, and time to operation, in affecting the accuracy of MRI evaluation of residual tumor size following NAC treatment. A total of 98 patients were studied. Univariate analysis revealed significant predictors including tumor type, morphology, ER, and MR scanner. Multivariate regression analyses demonstrated that only tumor type, tumor morphology, ER status, and HER-2 were independent predictors (all p<0.05). MRI diagnosis is less accurate in cancers with lobular component, cancers presenting non-mass-like enhancements, and cancers with ER positive and HER-2 negative status.